Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

  * Stage IIIB (with confirmed malignant pleural effusion), stage IV, or recurrent disease
  * Mixed tumors categorized by the predominant cell type are allowed provided no small cell elements exist

    * Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy
* Measurable disease as defined by RECIST criteria
* No squamous cell carcinoma (group 1)
* No history of brain metastases (group 1)

  * History of treated brain metastases allowed provided patient is not taking steroids and anti-seizure mediation (group 2)

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Bilirubin ≤ 1.5 mg/dL
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN with liver metastases)
* AST and ALT ≤ 3 times ULN (≤ 5 times ULN with liver metastases)
* INR \< 1.5 or PTT normal (group 1)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during (groups 1 and 2) and for 6 months after completion of study treatment (group 1)
* No preexisting peripheral neuropathy ≥ grade 2
* Must be able to swallow tablets
* No cardiovascular condition, including any of the following:

  * Myocardial infarction within the past 6 months
  * Cerebrovascular ischemia or stroke within the past 6 months
  * NYHA congestive heart failure \> class II
  * Unstable angina pectoris
  * Serious cardiac arrhythmia requiring medication
  * Significant vascular disease
  * Symptomatic peripheral vascular disease
* No concurrent medical condition, psychiatric illness, or limitations that would limit study compliance
* No ongoing active infection or ongoing fever within the past 6 months
* No history of uncontrolled hypertension, defined as blood pressure ≥ 150/90 mm Hg despite being on a stable regimen of anti-hypertensive therapy
* No serious nonhealing wound, ulcer, or bone fracture within the past 4 weeks
* No ongoing or active infection
* No history of thrombotic or hemorrhagic disorders, bleeding diathesis, or coagulopathy (group 1)
* No bleeding \> grade 2 or any bleeding requiring intervention within the past 4 weeks (group 1)
* No history of gross hemoptysis (defined as \> ½ teaspoon of bright red blood) (group 1)
* Urine protein:creatinine (UPC) ratio \< 1.0 by spot urinalysis

  * For UPC ratio \> 0.5, a 24-hour urine protein must be obtained and the urine protein level must be \< 1,000 mg (group 1)
* None of the following conditions (group 1):

  * Grade II or greater peripheral vascular disease
  * Abdominal fistula
  * Gastrointestinal perforation
  * Intra-abdominal abscess
* No known hypersensitivity to any component of bevacizumab (group 1)
* No history of hypertensive crisis or hypertensive encephalopathy (group 1)

PRIOR CONCURRENT THERAPY:

* More than 4 weeks since prior major surgical procedure
* More than 7 days since prior minor surgical procedure
* No prior chemotherapy for advanced NSCLC

  * Postoperative adjuvant chemotherapy for previously resected NSCLC allowed if last dose was given \> 1 year ago
* More than 3 weeks since prior radiation therapy and recovered
* More than 3 weeks since prior immunotherapy and/or hormonal therapy (not including hormone replacement therapy or contraceptives) and recovered
* More than 14 days since prior enzyme inducing anti-epileptic drugs (EIAEDs)
* More than 10 days since prior and no concurrent daily treatment with acetylsalicylic acid (\> 325 mg/day) or NSAIDs known to inhibit platelet function for chronic conditions (group 1)
* No concurrent major surgical procedure (group 1)
* No concurrent carbamazepine, phenobarbital, or phenytoin
* No concurrent therapeutic anticoagulation (group 1)

  * Prophylactic anticoagulation of venous access devices is allowed
* No concurrent treatment with dipyridamole, ticlopidine, clopidogrel, or cilostazol (group 1)
* No concurrent combination antiretroviral therapy for HIV-positive patients